Efficacity and Safety of Metformin XR in CKD Stage 1 to 3

• Status: Unknown status
• Trial end date: 2020-08-30
• Target enrollment: 0
• Participant gender: All

Summary

There is limited data availability on effect of Metformin XR on 24-h plasma glucose, and there is no available data in chronic kidney disease (CKD). The planned study aims to provide data on glucose plasma level in relation to metformin plasma level in Diabetes Type II patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire, Amiens
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Type 2 diabetes patients aged between 18 and 80 years requiring metformin (and any other antidiabetic treatment)

Exclusion Criteria:

• Pregnancy and lactation

• Hyperlactatemia (> 2.5 mmol/L)

• No creatinine levels available since 3 months

• Severe hepatic insufficiency

• No liver function parameters available

• Need of investigation with iodized contrast media

• Hypersensitivity to metformin